Streetbeat News

Price Targets

CBRL

Piper Sandler analyst Brian Mullan has initiated coverage on Cracker Barrel Old (NASDAQ:CBRL) with a Neutral rating and a price target of $96.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:02 am

CAKE

Piper Sandler analyst Nicole Miller Regan has initiated coverage on Cheesecake Factory (NASDAQ:CAKE) with a Neutral rating and a price target of $36.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:02 am

BLMN

Piper Sandler analyst Brian Mullan has initiated coverage on Bloomin Brands (NASDAQ:BLMN) with a Neutral rating and a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:01 am

PLAY

Piper Sandler analyst Nicole Miller Regan has initiated coverage on Dave & Buster's Enter (NASDAQ:PLAY) with an Overweight rating and a price target of $56.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:59 am

BJRI

Piper Sandler analyst Nicole Miller Regan has initiated coverage on BJ's Restaurants (NASDAQ:BJRI) with a Neutral rating and a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:58 am

FWRG

Piper Sandler analyst Nicole Miller Regan has initiated coverage on First Watch Restaurant Gr (NASDAQ:FWRG) with an Overweight rating and a price target of $22.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:57 am

TXRH

Piper Sandler analyst Brian Mullan has initiated coverage on Texas Roadhouse (NASDAQ:TXRH) with an Overweight rating and a price target of $126.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:51 am

EXPI

BTIG analyst Soham Bhonsle has initiated coverage on eXp World Holdings (NASDAQ:EXPI) with a Sell rating and a price target of $14.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:50 am

COMP

BTIG analyst Soham Bhonsle has initiated coverage on Compass (NYSE:COMP) with a Buy rating and a price target of $5.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:49 am

BBIO

Jefferies analyst Eun Yang has downgraded BridgeBio Pharma (NASDAQ:BBIO) from Buy to Hold, while raising the price target from $24 to $33.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 8:46 am